Page 9 - Sohini Das

Sun Pharma Q2 net profit rises 2.5% to ₹3,118 crore on India, EM growth

Sun Pharma's Q2FY26 profit rose to Rs 3,118 crore as India, emerging markets, and rest of world drove growth; US revenues fell 4.1% despite strong gains in innovative medicines

M&M Q2 results: Profit rises 16% on strong auto and farm showing

The company reported consolidated PAT of ₹3,673 crore and 22% revenue growth in Q2 FY26, led by robust SUV sales, record tractor volumes, and higher margins across segments

'Bumper' October as two-wheeler retail sales top 2.8 million units

Hero MotoCorp nears 1 million retail sales, Bajaj tops EV chart as strong rural demand and GST boost lift festive momentum

GST 2.0 drives two-wheeler owners to car showrooms, boosts Maruti

GST 2.0 price cuts are bringing a new set of first-time car buyers into Maruti showrooms, with small car bookings rising sharply and a focused campaign launched to ease financing

October car retail outpaces OEM dispatches to dealers, aided by GST reforms

Retail sales, however, outpaced wholesales as vehicles continued to move swiftly out of showrooms

USFDA's new biosimilar norms to woo more players, fast-track mkt entry

Indian cos like Biocon, DRL, Intas, Lupin stand to benefit from the proposed move

Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO from April 2026

Umang Vohra joined Cipla in 2015 as global chief financial and strategy officer and thereafter served as the company's MD & GCEO since 2016

Results preview: Pharma sales may be up 9-10% in Q2 on robust domestic biz

Domestic business and exports are expected to be a shot in the arm; hospitals and diagnostics to lag

This is the start of Hyundai India's next phase of growth: Tarun Garg

Hyundai veteran Tarun Garg will succeed Unsoo Kim as MD & CEO from Jan 1, 2026, marking a new chapter in the automaker's India journey

Q2 results preview: Robust volumes likely drove auto sector growth

But margins may have lost traction due to higher discounts, ad spends

Electric PV sales more than double in September; Tata Motors leads

New entrant Tesla also retailed 64 vehicles in September, data from the Federation of Automobile Dealers Associations (Fada) showed

A deadly dose of neglect: Bitter truth behind cough syrup scare

Bottled negligence: DEG contamination exposes gaps in inspections, leaving pharma units from Gujarat to Kerala under the microscope

Super-specialty hospitals may benefit from CGHS rate revision: Analysts

The new rules introduce a multi-dimensional rate structure based on three key parameters

Mercedes clocks best ever Navaratri with retail sales of 2,500 cars

After a sluggish July-August, Mercedes-Benz India posts record Navratri sales on GST cut boost; entry-level models lag but GLA under Rs 50 lakh may revive demand

Analysts expect Indian drugmakers to strike US deals to avoid tariff blow

If Sun Pharma is able to strike a Pfizer-like deal, it may avoid US tariff in near term, say experts

Tata Motors stock may face near-term volatility post demerger: Analysts

Analysts expect Tata Motors' stock to face near-term volatility after the PV-CV demerger, with JLR's production resumption and festive demand outlook key monitorables

TaMo invests ₹120 cr in Freight Tiger, raises total commitment to ₹270 cr

Tata Motors raised its Freight Tiger investment to Rs 270 crore with a fresh Rs 120 crore infusion, lifting its stake to 42-46 per cent to back AI-led logistics solutions

M&M to sell Finnish subsidiary Sampo Rosenlew to TERA for ₹52 crore

Mahindra & Mahindra will divest its Finnish arm Sampo Rosenlew Oy, maker of combine harvesters and forestry machines, to TERA for Rs 52 crore under a share purchase agreement

Tariff uncertainties may spur rise in third-party pharma manufacturing

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

Indian pharma firms likely to dodge immediate impact of Trump's tariff

Trump's 100% tariffs on branded drugs will spare Indian generics, though analysts see exposure for Sun Pharma, Biocon and Aurobindo, with Jubilant Pharmova set to benefit